Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.5%

10 terminated/withdrawn out of 69 trials

Success Rate

79.2%

-7.3% vs industry average

Late-Stage Pipeline

29%

20 trials in Phase 3/4

Results Transparency

50%

19 of 38 completed trials have results

Key Signals

10 recruiting19 with results6 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2
25(37.3%)
Phase 1
20(29.9%)
Phase 3
15(22.4%)
Phase 4
5(7.5%)
N/A
2(3.0%)
67Total
Phase 2(25)
Phase 1(20)
Phase 3(15)
Phase 4(5)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (69)

Showing 20 of 69 trials
NCT06898450Phase 1Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Role: collaborator

NCT05869669Phase 2Completed

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Role: collaborator

NCT06547489Phase 2Recruiting

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Role: collaborator

NCT06793397Phase 3Recruiting

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Role: collaborator

NCT07542704Phase 1Not Yet Recruiting

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

Role: collaborator

NCT04762069Phase 2Active Not Recruiting

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Role: collaborator

NCT05718817Phase 3Enrolling By Invitation

An Open-label Study of XEN1101 in Epilepsy

Role: collaborator

NCT07115329Phase 2Recruiting

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Role: collaborator

NCT06815471Phase 2Recruiting

CRF2 Agonist for the Treatment of Worsening Heart Failure

Role: collaborator

NCT05614063Phase 3Completed

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Role: collaborator

NCT05667142Phase 3Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Role: collaborator

NCT05716100Phase 3Recruiting

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Role: collaborator

NCT06605105Phase 3Enrolling By Invitation

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

Role: collaborator

NCT06671938Phase 2Active Not Recruiting

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

Role: collaborator

NCT06963216Phase 3Recruiting

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Role: collaborator

NCT06712407Phase 4Recruiting

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

Role: collaborator

NCT03574363Phase 2Completed

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

Role: collaborator

NCT05462106Phase 1Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Role: collaborator

NCT06051721Phase 2Active Not Recruiting

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)

Role: collaborator

NCT05658510Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

Role: collaborator